<table border="1" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td valign="top">Concomitant Drug<content stylecode="bold"> </content>
</td>
<td valign="top">Effect on Concentration of Lamotrigine or Concomitant Drug<content stylecode="bold"></content>
</td>
<td valign="top">Clinical Comment<content stylecode="bold"> </content>
</td>
</tr>
<tr>
<td valign="top">Estrogen-containing oral Contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td valign="top">↓ lamotrigine   <br/>
<br/>↓ levonorgestrel</td>
<td valign="top">Decreased lamotrigine levelsapproximately 50%. <br/>
<br/>Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td valign="top">Carbamazepine and carbamazepine epoxide<content stylecode="bold"> </content>
</td>
<td valign="top">↓ lamotrigine <br/> ? CBZ epoxide</td>
<td valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.<br/>May increase carbamazepine epoxide levels.</td>
</tr>
<tr>
<td valign="top">Phenobarbital/Primidone<content stylecode="bold"></content>
</td>
<td valign="top">↓ lamotrigine<content stylecode="bold"></content>
</td>
<td valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr>
<td valign="top">Phenytoin (PHT)<content stylecode="bold"></content>
</td>
<td valign="top">↓ lamotrigine<content stylecode="bold"></content>
</td>
<td valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr>
<td valign="top">Rifampin<content stylecode="bold"></content>
</td>
<td valign="top">↓ lamotrigine<content stylecode="bold"></content>
</td>
<td valign="top">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr>
<td valign="top">Valproate<content stylecode="bold"></content>
</td>
<td valign="top">↑ lamotrigine <br/> <br/>? valproate<content stylecode="bold"> </content>
</td>
<td valign="top">Increased lamotrigine concentrations slightly more than 2-fold.<br/>
<br/>Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.</td>
</tr>
</tbody>
</table>